Testing nemolizumab for lichen planopilaris
Treatments studied
Part of Skin clinical trials.
This study tests a new medication called nemolizumab for people with lichen planopilaris (LPP), a type of scarring hair loss. It aims to see if the drug can help reduce scalp itching and improve the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with lichen planopilaris (LPP) by a doctor.
- You have moderate to severe scalp itching (average score of 4 or higher on a 0-10 scale in the past week).
- You haven't taken nemolizumab before, and you are not currently on certain medications like JAK inhibitors, biologics, or DMARDs without a washout period.
- You are willing to possibly have a small scalp biopsy for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
This trial tests a new medication called brepocitinib to treat lichen planopilaris (LPP), a condition that causes scarring and hair loss on the scalp. The study aims to see if this drug can reduce symptoms and help hair regrow.
This study tests a new injectable medication called nemolizumab to see if it can reduce itching in women with lichen sclerosus affecting the genital area. If you have severe itching that hasn't been fully controlled by steroid creams, this might be an option to explore.
This trial tests a pill called upadacitinib to see if it can reduce painful mouth sores and scalp hair loss caused by lichen planus. It may help people who have not gotten better with topical steroid creams.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This study tests a new medication called nemolizumab to see if it can reduce the intense itching caused by certain liver diseases (PBS or PSC). The drug may help block a protein that triggers itch signals, offering relief for people whose current treatments haven't worked well.
Hear when a new Lichen Plano-Pilaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.